World Pharma Today

  Noah Nasser, CEO of  datma Most pharmaceutical companies have already invested heavily in real-world data (RWD). These internal datasets, often curated over years, serve as the foundation for ongoing research and analysis. They often represent significant investment in time, budget, and coordination across internal teams and systems. But even robust internal datasets can fall short when new analytical needs or questions arise, particularly in the context of targeted therapies where biomarker specific insights are essential.  When a stakeholder asks a question about a subpopulation defined by a biomarker, mutation type, or clinical context, the existing dataset may not contain the patients needed to answer it. The missing data might be subtle, such as biomarker status or specific genomic features, but they are often essential. This doesn’t mean the internal dataset is flawed, it reflects the evolving nature of oncology and the reality that new questions often demand new ...

  Sanome’s MEMORI becomes the first UK‑built, Certified Class IIb Software-as-a-Medical Device for real-time infection prediction, ahead of NHS rollout and FDA approval. AI tool that spots hospital infections up to 72 hours early, newly backed by former health minister Lord Bethell, Prof Carole Longson and Dr Arrash Yassaee Sanome’s MEMORI becomes the first UK-developed AI medical device that predicts and detects infections earlier, to achieve Class IIb Medical Device CE certification and MHRA approval The technology delivers real-time alerts to clinical teams with no disruption, helping ease pressure on overburdened hospitals, supporting the new NHS 10-Year Plan’s focus on prevention and early intervention Sanome, a company building Clinical Decision Support tools to detect emerging health risks, has secured Class IIb CE certification and MHRA approval for MEMORI – an AI-enabled warning system for the early prediction/prevention of healthcare‑associated infections (HAIs) – at the ...

  Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. In a significant step toward strengthening India’s efforts in nutrition and metabolism research, Agilent Technologies and the Tata Institute of Fundamental Research (TIFR), Hyderabad have announced a strategic collaboration to support ARUMDA (Advanced Research Unit on Metabolism, Development, and Aging). This partnership brings together Agilent’s global expertise in analytical science with TIFR’s research endeavors to address the growing burden of non-communicable diseases (NCDs) and malnutrition in the country. A key outcome of this collaboration is the launch of the Agilent–TIFR Center of Translational Research in Hyderabad. The center will play a pivotal role in supporting the Advanced Research Unit on Metabolism, Development & Aging (ARUMDA)—one of India’s most ambitious government-supported initiatives in human health. ARUM...

  Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company. Sino Biological US, Inc. proudly unveils  ProPure™ , an  industry-leading line of ultra-pure, endotoxin-free recombinant proteins ,  fully produced in the USA  at its state-of-the-art Center for Bioprocessing (C4B) facility in Houston, Texas. This new product line is specifically engineered to meet the rigorous demands of immunology research, vaccine development, animal studies, cell and gene therapy, and therapeutic protein manufacturing. The newly released proteins are manufactured using advanced purification and production technologies, ensuring endotoxin levels below the limit of quantification (LOQ). By leveraging mammalian expression systems and proprietary purification protocols, the C4B delivers high-purity proteins tailored for sensitive applications where even trace endotoxin contamination can comp...

  Accomplished industry leader to continue driving growth and product expansion across life sciences, flavors, fragrances, and specialty segments Greenfield Global Inc., a leading global producer, manufacturer, and distributor of high-purity and specialty alcohols, solvents, and custom solutions, announced today the appointment of Yvonne (Vey) Garofalo as Executive Vice President of the Specialty Chemicals and Ingredients (SC&I) business unit, which consists of the life science; food, flavor, and fragrance; personal care; and specialty business segments. Garofalo brings more than two decades of experience and a proven track record of strategic leadership and commercial excellence to Greenfield. Garofalo’s background in the life science and specialty chemical sectors, experience with both direct sales and distributor-based models, as well as her leadership in managing various global functions including Commercial, Operations, Finance, and R&D, positions her exceptionally wel...

default Pharma teams can now assess biomarker coverage across datma’s federated network with no cost, contracts, or IT support required. datma, a leader in federated real-world data access, today announced the launch of the Federated Biomarker Explorer, a new application that allows pharmaceutical teams to evaluate real-world biomarker coverage across datma’s federated network of participating data contributors before entering into a formal data partnership. This tool is designed to help teams answer a critical question early in the data sourcing process: Does this dataset contain the patient populations we need? The Federated Biomarker Explorer provides aggregate, cohort-level visibility into biomarker presence across the datma federated network. Teams can filter by a range of clinical and demographic attributes to assess feasibility. No data integration, procurement involvement, or internal IT support is required, making the application immediately accessible for teams looking to val...

  Dr. Oliver Okle is a product and service manager at Vetter The global CDMO market is projected to more than double from $161 billion in 2023 to $322.76 billion by 20331. This is only a portion of the rapid growth we’re witnessing in the broader pharmaceutical and biotech industry, driven by innovation and increased investment in research and development (R&D)2. This growth underscores the need for CDMOs to invest in advanced infrastructure, technologies, and process optimizations to stay ahead in the evolving market. In this interview, Dr. Oliver Okle, Product and Service Manager at Vetter, a globally operating CDMO, discusses the importance of trend scouting and how it helps outsourcing partners stay competitive. Dr. Okle, what are the key factors driving the rapid expansion of the pharmaceutical and biotech industries? In my experience, the primary drivers are innovation and increased R&D investment. The significant growth in the CDMO market, and the rise in R&D sp...